文献速递细菌感染、耐药与抗菌药物

达托霉素联合β-内酰胺治疗MRSA血流感染的回顾性队列研究

Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

这项在2个学术医疗中心开展的2008至2018年回顾性对比队列研究,纳入229例接受达托霉素≥72小时且培养采集后≤5天启动治疗的MRSA血流感染成人患者,比较达托霉素联合β-内酰胺(DAP+BL)与达托霉素单药治疗的临床结局。

要点

  • 达托霉素联合β-内酰胺与MRSA血流感染复合临床失败风险降低相关。
  • 预设亚组分析结果与主分析一致,支持联合治疗用于侵袭性MRSA感染。

核心结论

  • 在MRSA血流感染患者中,达托霉素联合β-内酰胺与改善的临床结局相关。

研究设计与样本

  • 回顾性对比队列研究,2008至2018年在2个学术医疗中心开展,共纳入229例患者(DAP+BL组72例,DAP单药组157例)。

主要发现

  • 基于感染复杂性和基线健康状态的预设亚组调整分析结果与主分析一致。

关键数值与推荐

  • 纳入标准:成人MRSA血流感染,达托霉素治疗≥72小时且启动于培养采集后≤5天。
  • DAP+BL组定义:接受β-内酰胺≥24小时且启动于达托霉素开始后≤24小时。
  • 主要结局:复合临床失败,定义为60天全因死亡和/或60天复发。

临床怎么用

  • 对于MRSA血流感染,可考虑在达托霉素基础上联合β-内酰胺以改善临床结局。
  • 该结果支持开展进一步研究评估联合治疗对侵袭性MRSA感染的影响。

局限性

  • 回顾性设计可能残留混杂。
  • 仅纳入2个学术医疗中心,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mounting evidence suggests the addition of a β-lactam (BL) to daptomycin (DAP) results in synergistic in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) and bolsters the innate immune response to infection. This study's objective was to provide clinical translation to these experimental data and determine if DAP+BL combination therapy results in improved clinical outcomes compared with treatment with DAP alone in patients with MRSA bloodstream infections (BSIs). METHODS: This was a retrospective, comparative cohort study conducted at 2 academic medical centers between 2008 and 2018. Adults with MRSA BSI treated with DAP for ≥72 hours and initiated ≤5 days of culture collection were included. Patients who received a BL for ≥24 hours and initiated ≤24 hours of DAP comprised the DAP+BL group. The primary outcome was composite clinical failure (60-day all-cause mortality and/or 60-day recurrence). Analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW). RESULTS: A total of 229 patients were included (72 DAP+BL and 157 DAP). In unadjusted and IPTW-adjusted analyses, DAP+BL was associated with significantly reduced odds of clinical failure (odds ratio [OR], 0.362; 95% confidence interval [CI], .164-.801; adjusted OR, 0.386; 95% CI, .175-.853). Adjusted analyses restricted to prespecified subgroups based on infection complexity and baseline health status were consistent with the main analysis. CONCLUSIONS: The addition of a BL to DAP was associated with improved clinical outcomes in patients with MRSA BSI. This study provides support to ongoing and future studies evaluating the impact of combination therapy for invasive MRSA infections.Patients treated with daptomycin plus a β-lactam for MRSA bloodstream infection had lower odds of composite clinical failure defined as 60-day all-cause mortality and/or 60-day recurrence compared with patients treated with daptomycin monotherapy after adjusting for confounding variables using inverse probability of treatment weighting.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jorgensen SCJ, Zasowski EJ, Trinh TD, et al. Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. Clin Infect Dis. 2020. PMID: 31404468. doi:10.1093/cid/ciz746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。